Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Injury ; 50(9): 1507-1510, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31147183

RESUMO

BACKGROUND: Generally considered a sign of life, PEA is the most common arrhythmia encountered following pre-hospital traumatic cardiac arrest. Some recommend cardiac ultrasound (CUS) to determine cardiac wall motion (CWM) prior to terminating resuscitation efforts. This purpose of this study was to evaluate the outcomes of patients with traumatic cardiac arrest presenting with PEA, with and without CWM. METHODS: Trauma patients who underwent pre-hospital CPR were identified from the registries of two level-1 trauma centers. Pre-hospital management by emergency medical transport services was guided by advanced life support protocols. The on-duty trauma surgeon directed the resuscitations and performed or supervised CUS and determined CWM. RESULTS: Among 277 patients who underwent pre-hospital CPR, 110 patients had PEA on arrival to ED. 69 (62.7%) were injured by blunt mechanisms. Median CPR duration was 20.0 and 8.0 min for pre-hospital and ED, respectively. Sixty-three patients (22.7%) underwent resuscitative thoracotomy. One hundred seventy-two patients (62.1%) received CUS and of these 32 (18.6%) had CWM. CWM was significantly associated with survival to hospital admission (21.9% vs. 1.4%; P < 0.001); however, no patient with CUS survived to hospital discharge. Overall, only one patient with PEA on arrival survived to discharge. CONCLUSION: Following pre-hospital traumatic cardiac arrest, PEA on arrival portends death. Although CWM is associated with survival to admission, it is not associated with meaningful survival. Heroic resuscitative measures may be unwarranted for PEA following pre-hospital traumatic arrest, regardless of CWM.


Assuntos
Reanimação Cardiopulmonar/métodos , Serviços Médicos de Emergência/métodos , Parada Cardíaca/fisiopatologia , Pulso Arterial/instrumentação , Adulto , Reanimação Cardiopulmonar/mortalidade , Eletrocardiografia , Feminino , Parada Cardíaca/classificação , Parada Cardíaca/mortalidade , Parada Cardíaca/terapia , Humanos , Masculino , Futilidade Médica , Pessoa de Meia-Idade , Estudos Retrospectivos , Estatísticas não Paramétricas , Adulto Jovem
2.
Chest ; 104(3): 831-4, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8365297

RESUMO

HYPOTHESIS: Intravenous magnesium sulfate improves objective measures of expiratory flow in patients with acute severe exacerbations of asthma. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Urban emergency department. PARTICIPANTS: Forty-eight asthmatic patients aged 18 to 60 years with initial peak expiratory flow rate (PEFR) < 200 L/min who failed to double their initial PEFR after two standardized albuterol treatments. INTERVENTIONS: Subjects were randomized to three groups: a loading dose of magnesium sulfate, 2 g IV over 20 min followed by 2 g/h over 4 h (infusion), magnesium sulfate, 2 g over 20 min followed by placebo infusion (bolus), or placebo loading dose and infusion (placebo). All subjects received standardized aminophylline and steroid therapy. MEASUREMENTS: The PEFR and FEV1 were measured at the start of the loading dose, and 20, 50, 80, 140, 200, and 260 min later using a water-displacement spirometer. Changes from baseline were compared by one-way analysis of variance for repeated measures. RESULTS: Magnesium sulfate administration did not at any time significantly improve either FEV1 (F = 0.036, p = 0.96) or PEFR (F = 0.51, p = 0.61). This study had the power to detect a PEFR difference of 26 L/min and a FEV1 difference of 0.19 L between groups (beta = 0.20, alpha = 0.05 two-tailed significance). CONCLUSION: Use of IV magnesium sulfate in addition to standard therapy does not provide clinically meaningful improvement of objective measures of expiratory flow in patients with moderate to severe asthma exacerbations.


Assuntos
Asma/tratamento farmacológico , Magnésio/administração & dosagem , Ventilação Pulmonar , Doença Aguda , Adolescente , Adulto , Aminofilina/administração & dosagem , Asma/fisiopatologia , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Volume Expiratório Forçado , Humanos , Infusões Intravenosas , Injeções Intravenosas , Masculino , Metilprednisolona/administração & dosagem , Pessoa de Meia-Idade , Pico do Fluxo Expiratório
3.
Emerg Med Clin North Am ; 18(4): 723-43, vi, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11130935

RESUMO

The development of potent inhibitors of platelet aggregation has led to significant decreases in morbidity and mortality rates among patients undergoing percutaneous coronary intervention. Clinical trials have demonstrated that agents that block glycoprotein IIb/IIIa receptor-mediated platelet aggregation have an outcome benefit when used acutely in patients with chest pain and ST depression or elevated cardiac enzymes, leading to the integration of these agents into emergency medicine clinical practice. This article provides an overview of the pathophysiology of acute coronary syndrome and the pharmacology of platelet inhibition and reviews the evidence from the clinical trials pertaining to the use of these agents in the emergency department.


Assuntos
Trombose Coronária/terapia , Inibidores da Agregação Plaquetária/uso terapêutico , Angioplastia Coronária com Balão , Aspirina/efeitos adversos , Aspirina/uso terapêutico , Ensaios Clínicos como Assunto , Terapia Combinada , Doença da Artéria Coronariana/complicações , Doença da Artéria Coronariana/fisiopatologia , Trombose Coronária/tratamento farmacológico , Trombose Coronária/etiologia , Análise Custo-Benefício , Inibidores de Ciclo-Oxigenase/efeitos adversos , Inibidores de Ciclo-Oxigenase/uso terapêutico , Emergências , Humanos , Infarto do Miocárdio/tratamento farmacológico , Inibidores da Agregação Plaquetária/efeitos adversos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/efeitos adversos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Síndrome
5.
Am J Emerg Med ; 18(4): 435-40, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10919534

RESUMO

The emergency physician may be called on at any time to evaluate a patient with a pacemaker. Although current models are very reliable, malfunctions occur. This review discusses the basic components of the antibradycardic pacemaker, which malfunctions can be expected to occur, and how to evaluate an improperly functioning unit. In addition, recommendations for disposition are discussed.


Assuntos
Marca-Passo Artificial , Desenho de Equipamento , Falha de Equipamento , Parada Cardíaca/terapia , Humanos , Infarto do Miocárdio/diagnóstico
6.
Stroke ; 24(5): 747-55; discussion 755-6, 1993 May.
Artigo em Inglês | MEDLINE | ID: mdl-8488532

RESUMO

BACKGROUND: Brain ischemia and reperfusion produce profound protein synthesis alterations, the extent and persistence of which are dependent on the nature of the ischemia, the brain region, the cell layer within a region, and the particular proteins studied. After transient ischemia, most brain regions recover their protein synthesis capability; however, recovery in the selectively vulnerable areas is poor. It is unknown whether this phenomenon itself provokes or is a consequence of the process of neuronal death. SUMMARY OF REVIEW: Protein synthesis suppression during ischemia is due to energy depletion, but this is quickly reversed upon recirculation. Reperfusion does not appear to damage DNA or transcription mechanisms, although there are changes in the profile of transcripts being made. Similarly, purified ribosomes isolated from reperfused brains can make the normal repertoire of proteins and heat-shock proteins. However, during early reperfusion, newly synthesized messenger RNAs appear to accumulate in the nucleus; this alteration in RNA handling could reflect disruption at any of several steps, including posttranscriptional processing, nuclear pore transport, cytoskeletal binding, or formation of the translation initiation complex. Another mechanism that may be responsible for protein synthesis suppression during late reperfusion is progressive membrane destruction, with consequent shifts in the concentration of ions crucial for ribosomal function. CONCLUSIONS: Protein synthesis suppression after ischemia likely involves a progression of multiple mechanisms during reperfusion. Although the recent work reviewed here offers new insight into the potential mechanisms disrupting protein synthesis, detailed understanding will require further investigation.


Assuntos
Química Encefálica , Isquemia Encefálica/metabolismo , Biossíntese de Proteínas , Animais , Isquemia Encefálica/patologia , Morte Celular , Neurônios , Proteínas Proto-Oncogênicas/biossíntese , RNA Mensageiro/metabolismo , Reperfusão
7.
Ann Emerg Med ; 25(6): 809-17, 1995 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7755206

RESUMO

STUDY HYPOTHESIS: We attempted to determine whether the reduced egress of mRNA from brain nuclei following in vivo ischemia and reperfusion is caused by direct damage to the nuclear pore-associated NTPase that impairs the system for nuclear export of polyadenylated, or poly(A)+, mRNA. DESIGN: Prospective animal study. INTERVENTIONS: NTPase activity and poly(A)+ mRNA transport were studied in nuclear envelope vesicles (NEVs) prepared from canine parietal cortex isolated after 20 minutes of ischemia or 20 minutes of ischemia and 2 or 6 hours of reperfusion. RESULTS: Brain NEV NTPase Michaelis-Menten constant (Km) and maximum uptake velocity (Vmax) and the ATP-stimulated poly(A)+ mRNA egress rates were not significantly affected by ischemia and reperfusion. In vitro exposure of the NEVs to the OH. radical-generating system completely abolished NTPase activity. CONCLUSION: We conclude that brain ischemia and reperfusion do not induce direct inhibition of nucleocytoplasmic transport of poly(A)+ mRNA. This suggests that the nuclear membrane is not exposed to significant concentrations of OH. radical during reperfusion.


Assuntos
Hidrolases Anidrido Ácido/farmacocinética , Isquemia Encefálica/metabolismo , RNA Mensageiro/metabolismo , Reperfusão , Animais , Transporte Biológico , Cães , Parada Cardíaca/metabolismo , Radical Hidroxila/metabolismo , Membrana Nuclear/metabolismo , Nucleosídeo-Trifosfatase , Estudos Prospectivos
8.
Exp Neurol ; 124(2): 351-6, 1993 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-7507063

RESUMO

Rat brain nuclear proteins were examined for tyrosine phosphorylation after resuscitation from a 10-min cardiac arrest. Insulin (1 unit/kg intravenously), given immediately after resuscitation, caused a marked increase in tyrosine phosphorylation of a 90-kDa brain protein. This effect occurred without hypoglycemia and was not observed after insulin administration in previously insulinopenic, diabetic, nonischemic animals. Insulin-responsive tyrosine phosphorylation of a specific 90-kDa protein during reperfusion may represent insulin stimulation of a neuroprotective brain response to an ischemic insult, consistent with recent observations that insulin administration during reperfusion protects selectively vulnerable neurons from postischemic death.


Assuntos
Encéfalo/metabolismo , Parada Cardíaca/metabolismo , Insulina/farmacologia , Ataque Isquêmico Transitório/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Reperfusão , Análise de Variância , Animais , Encéfalo/efeitos dos fármacos , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Diabetes Mellitus Experimental/metabolismo , Parada Cardíaca/fisiopatologia , Masculino , Reperfusão Miocárdica , Fosfoproteínas/isolamento & purificação , Fosfoproteínas/metabolismo , Fosforilação , Fosfotirosina , Ratos , Ratos Wistar , Ressuscitação , Tirosina/análogos & derivados , Tirosina/análise , Tirosina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA